<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:53:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9832225" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9832225</identifier>
        <datestamp>2023-01-12</datestamp>
        <setSpec>jclinhype</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jch14591" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Hypertens (Greenwich)</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Hypertens (Greenwich)</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1751-7176</journal-id>
              <journal-id journal-id-type="publisher-id">JCH</journal-id>
              <journal-title-group>
                <journal-title>The Journal of Clinical Hypertension</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1524-6175</issn>
              <issn pub-type="epub">1751-7176</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9832225</article-id>
              <article-id pub-id-type="pmcid">PMC9832225</article-id>
              <article-id pub-id-type="pmc-uid">9832225</article-id>
              <article-id pub-id-type="pmid">36541028</article-id>
              <article-id pub-id-type="pmid">36541028</article-id>
              <article-id pub-id-type="doi">10.1111/jch.14591</article-id>
              <article-id pub-id-type="publisher-id">JCH14591</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Short Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Short Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Inflammation moderates the effects of lifestyle modification on neurocognition among individuals with resistant hypertension</article-title>
                <alt-title alt-title-type="left-running-head">AVORGBEDOR et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jch14591-cr-0001" contrib-type="author">
                  <name>
                    <surname>Avorgbedor</surname>
                    <given-names>Forgive</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jch14591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0002" contrib-type="author">
                  <name>
                    <surname>Blumenthal</surname>
                    <given-names>James A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0003" contrib-type="author">
                  <name>
                    <surname>Hinderliter</surname>
                    <given-names>Alan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0004" contrib-type="author">
                  <name>
                    <surname>Ingle</surname>
                    <given-names>Krista</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0005" contrib-type="author">
                  <name>
                    <surname>Lin</surname>
                    <given-names>Pao‐Hwa</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0006" contrib-type="author">
                  <name>
                    <surname>Craighead</surname>
                    <given-names>Linda</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0007" contrib-type="author">
                  <name>
                    <surname>Tyson</surname>
                    <given-names>Crystal</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0008" contrib-type="author">
                  <name>
                    <surname>Kraus</surname>
                    <given-names>William</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0009" contrib-type="author">
                  <name>
                    <surname>Sherwood</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jch14591-cr-0010" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Patrick J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jch14591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>patrick_smith@med.unc.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jch14591-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">School of Nursing</named-content>
                <institution>University of North Carolina at Greensboro</institution>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jch14591-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychiatry and Behavioral Sciences</named-content>
                <institution>Duke University Medical Center</institution>
                <city>Durham</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jch14591-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of North Carolina at Chapel Hill</institution>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jch14591-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>Duke University Medical Center</institution>
                <city>Durham</city>
                <named-content content-type="country-part">North Carolina</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jch14591-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Psychology</named-content>
                <institution>Emory University</institution>
                <city>Atlanta</city>
                <named-content content-type="country-part">Georgia</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Patrick J. Smith, PhD, MPH Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA.<break/>Email: <email>patrick_smith@med.unc.edu</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <volume>25</volume>
              <issue seq="140">1</issue>
              <issue-id pub-id-type="doi">10.1111/jch.v25.1</issue-id>
              <fpage>106</fpage>
              <lpage>110</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>06</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>30</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>09</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 Wiley Periodicals LLC.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">The Journal of Clinical Hypertension</italic> published by Wiley Periodicals LLC.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JCH-25-106.pdf"/>
              <abstract>
                <title>Abstract</title>
                <p>Individuals with resistant hypertension (RH) have the greatest risk of cerebrovascular disease and cognitive impairment among individuals with hypertension. Elevated levels of pro‐inflammatory cytokines may represent a critical yet unexamined factor influencing the impact of healthy lifestyle changes on cognitive function. We explored the influence of inflammation on changes in cognition following lifestyle modification among individuals with RH participating in the TRIUMPH clinical trial. One hundred forty participants with RH completed a battery of neurocognitive tests along with the inflammatory marker C‐reactive protein (hsCRP) and were subsequently randomized to an intensive 4‐month lifestyle modification intervention or to education and physician advice control. Results indicated that the effects of lifestyle modification on Executive Function and Learning were moderated by pre‐intervention hsCRP levels (<italic toggle="yes">P</italic> = .049), with treatment efficacy increasing across levels of baseline inflammation levels (low: <italic toggle="yes">d</italic> = 0.12; mild: <italic toggle="yes">d</italic> = 0.43; moderate: <italic toggle="yes">d</italic> = 0.81). We conclude that inflammatory profiles may help identify individuals more likely to improve executive functioning resulting from lifestyle modification.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jch14591-kwd-0001">cognitive function</kwd>
                <kwd id="jch14591-kwd-0002">inflammation</kwd>
                <kwd id="jch14591-kwd-0003">lifestyle modification</kwd>
                <kwd id="jch14591-kwd-0004">resistant hypertension</kwd>
              </kwd-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <page-count count="5"/>
                <word-count count="2924"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:11.01.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jch14591-cit-0016"><string-name><surname>Avorgbedor</surname><given-names>F</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hinderliter</surname><given-names>A</given-names></string-name>, et al. <article-title>Inflammation moderates the effects of lifestyle modification on neurocognition among individuals with resistant hypertension</article-title>. <source>J Clin Hypertens</source>. <year>2023</year>;<volume>25</volume>:<fpage>106</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1111/jch.14591</pub-id>
</mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <sec id="jch14591-sec-0010">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Hypertension is one of the primary causes of cardiovascular disease, stroke, Alzheimer's Disease, and Alzheimer's Disease and related dementias (AD/ADRD).<xref rid="jch14591-bib-0001" ref-type="bibr"><sup>1</sup></xref> Among individuals with hypertension, those with resistant hypertension (RH) appear to have the greatest risk of cerebrovascular disease and associated cognitive impairment.<xref rid="jch14591-bib-0002" ref-type="bibr"><sup>2</sup></xref> Although the deleterious effects of RH on cognitive function are likely multifactorial, emerging evidence suggests that elevated levels of pro‐inflammatory cytokines may be a critical, central mechanism by which RH worsens cognition.<xref rid="jch14591-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jch14591-bib-0004" ref-type="bibr"><sup>4</sup></xref> Indeed, recent reviews have emphasized that hypertension, CVD risk factors, and age‐related cognitive decline all share common underlying mechanisms of risk for cognitive decline, with inflammation serving as the most likely convergent mechanistic pathway.<xref rid="jch14591-bib-0005" ref-type="bibr"><sup>5</sup></xref> Understanding the overlapping influences of hypertension and inflammation are particularly important as recent consensus guidelines have advocated for targeted lifestyle modification as a preventive strategy to mitigate ADRD risk among vulnerable adults, with precision medicine frameworks emphasizing the use of elevated inflammatory cytokines to identify vulnerable middle‐aged adults for lifestyle changes.<xref rid="jch14591-bib-0005" ref-type="bibr"><sup>5</sup></xref>
</p>
              <p>Lifestyle modification, including exercise and dietary modification, is an established approach to improve both hypertension and cognitive function. The TRIUMPH clinical trial<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref> demonstrated that a comprehensive exercise and dietary program can improve blood pressure, weight, and CVD biomarkers,<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref> as well as improving neurocognitive function.<xref rid="jch14591-bib-0007" ref-type="bibr"><sup>7</sup></xref> Emerging evidence suggests that individual differences in CVD risk factors and background characteristics may moderate improvements neurocognition, particularly in the domain of executive function.<xref rid="jch14591-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jch14591-bib-0008" ref-type="bibr"><sup>8</sup></xref> Despite these reported individual differences and the potentially integral role of inflammation, to our knowledge no studies have examined inflammation as a potential moderator of improved cognitive function following lifestyle modification. Therefore, this brief report aimed to investigate the potential influence of individual differences in pre‐treatment inflammatory profiles on changes in cognition following lifestyle modification among RH participants in the TRIUMPH clinical trial.<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref>
</p>
            </sec>
            <sec id="jch14591-sec-0020">
              <label>2</label>
              <title>METHODS</title>
              <p>The methodology for the present report has been previously published.<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jch14591-bib-0007" ref-type="bibr"><sup>7</sup></xref> Briefly, the TRIUMPH study was a randomized clinical trial (RCT) designed to evaluate whether intensive lifestyle modification could reduce BP and improve CVD biomarker outcomes among 140 individuals with RH relative to an education and physician advice control condition.<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref> Details of the primary trial results and neurocognitive outcomes have been reported previously (NCT03001427 and NCT03001427).<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jch14591-bib-0007" ref-type="bibr"><sup>7</sup></xref> One hundred forty patients with RH were randomized with 2:1 allocation to either a 4‐month Center‐based Lifestyle intervention (C‐LIFE) or Standardized Education and Physician Advice (SEPA).</p>
              <p>Neurocognitive function was assessed by a battery of standard neurocognitive tests, which are detailed in the primary paper.<xref rid="jch14591-bib-0007" ref-type="bibr"><sup>7</sup></xref> The primary endpoint of the TRIUMPH cognitive study was Executive Function and Learning, with Memory and Processing Speed serving as secondary outcomes. Participants were also screened for dementia using the Montreal Cognitive Assessment test (MOCA).</p>
              <p>Inflammation was assessed sing high‐sensitivity C‐reactive protein (hsCRP), quantified by Lab Corp using commercial enzyme‐linked immunosorbent assay kits (R&amp;D Systems). Values exceeding 10 mg/dl were truncated at 10 mg/dL, consistent with contemporary analytical guidelines.</p>
              <sec id="jch14591-sec-0030">
                <label>2.1</label>
                <title>Data analysis</title>
                <p>All analyses were conducted using SAS 9.4 (Cary, North Carolina) and R 4.1.3 (<ext-link xlink:href="https://cran.r-project.org/" ext-link-type="uri">https://cran.r‐project.org/</ext-link>). General linear models were used to examine the potential moderating effect of baseline inflammation on 1) the relationship between vascular risk factors and cognitive function at baseline and 2) treatment‐related changes in cognitive function. Within each model, adjustment variables included age, education, biological sex, race (minority vs. non‐minority), Framingham Stroke Risk Profile (FSRP) score, creatinine, and hsCRP. For our analyses of treatment‐related changes in cognitive function, we also controlled for the baseline level of the respective cognitive outcome and group assignment. In order to test for potential moderation by baseline inflammatory markers, we tested for interactions between hsCRP and group assignment for potential treatment group moderation. We also incorporated follow‐up data collected at one‐year collected in a subset of participants prior to the onset of the COVID‐19 pandemic lockdown (<italic toggle="yes">n</italic> = 91). In order to account for missing data, multiple imputations were used (PROC MI) with 50 imputations. For analyses of follow‐up data, we used a repeated measures mixed model with an unstructured covariance matrix and the same covariates as our primary analyses above.</p>
                <p>Exploratory analyses were also conducted to examine the association between changes in putative causal treatment mechanisms (aerobic fitness, weight loss, dietary changes, and BP) and cognitive outcomes for the purposes of hypothesis generation. Model assumptions regarding linearity, independence, and normality of residuals were assessed and found to be acceptable prior to analysis. For explanatory purposes, we also characterized the sample by baseline levels of hsCRP. To do so, we utilized previously published hsCRP clinical thresholds from baseline assessments, with hsCRP levels of ≤2.0 mg/L, 2–5 mg/L, and ≥5.0 mg/L used to delineate normal, mildly elevated, and moderately elevated CRP groups. Following convention, hsCRP levels &gt; 10 mg/L were truncated for the purposes of analyses, and hsCRP was log‐transformed within regression models in order to preserve the normality of residuals.</p>
              </sec>
            </sec>
            <sec id="jch14591-sec-0040">
              <label>3</label>
              <title>RESULTS</title>
              <p>Examination of baseline hsCRP levels revealed that 49 individuals (35%) exhibited normal levels, 51 individuals (36%) exhibited mildly elevated levels, and 40 individuals (29%) exhibited moderately elevated levels. There were no baseline differences in hsCRP levels between treatment groups (<italic toggle="yes">P</italic> = .817). Examination of Table <xref rid="jch14591-tbl-0001" ref-type="table">1</xref> shows that higher hsCRP levels were associated with greater obesity (<italic toggle="yes">r</italic> = 0.45, <italic toggle="yes">P</italic> &lt; .001) and HOMA‐IR (<italic toggle="yes">r</italic> = 0.31, <italic toggle="yes">P</italic> &lt; .001), and younger age (<italic toggle="yes">r</italic> = −0.24, <italic toggle="yes">P</italic> = .004).</p>
              <table-wrap position="float" id="jch14591-tbl-0001" content-type="TABLE">
                <label>TABLE 1</label>
                <caption>
                  <p>Baseline demographic, clinical, and neurocognitive characteristics of the sample by CRP levels and treatment group. Scores within cognitive domains reflect global, mean‐rank scores where higher performance is consistent with better performance relative to other trial participants</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <col align="char" char="(" span="1"/>
                  <thead>
                    <tr>
                      <th align="left" rowspan="1" colspan="1"/>
                      <th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1"><bold>Low CRP</bold> (<italic toggle="yes">n</italic> = 49)</th>
                      <th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1"><bold>Mildly elevated CRP</bold> (<italic toggle="yes">n</italic> = 51)</th>
                      <th colspan="2" style="border-bottom:solid 1px #000000" align="left" rowspan="1"><bold>Moderately elevated CRP</bold> (<italic toggle="yes">n</italic> = 40)</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1">
                        <bold>Variable</bold>
                      </th>
                      <th align="left" rowspan="1" colspan="1"><bold>C‐LIFE</bold> (<italic toggle="yes">n</italic> = 35)</th>
                      <th align="left" rowspan="1" colspan="1"><bold>SEPA</bold> (<italic toggle="yes">n</italic> = 14)</th>
                      <th align="left" rowspan="1" colspan="1"><bold>C‐LIFE</bold> (<italic toggle="yes">n</italic> = 29)</th>
                      <th align="left" rowspan="1" colspan="1"><bold>SEPA</bold> (<italic toggle="yes">n</italic> = 22)</th>
                      <th align="left" rowspan="1" colspan="1"><bold>C‐LIFE</bold> (<italic toggle="yes">n</italic> = 26)</th>
                      <th align="left" rowspan="1" colspan="1"><bold>SEPA</bold> (<italic toggle="yes">n</italic> = 14)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <bold>Demographic and background characteristics</bold>
                      </td>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age, years</td>
                      <td align="char" rowspan="1" colspan="1">63.3 (9.3)</td>
                      <td align="char" rowspan="1" colspan="1">62.6 (9.7)</td>
                      <td align="char" rowspan="1" colspan="1">62.7 (8.4)</td>
                      <td align="char" rowspan="1" colspan="1">64.5 (9.4)</td>
                      <td align="char" rowspan="1" colspan="1">59.9 (8.2)</td>
                      <td align="char" rowspan="1" colspan="1">61.7 (9.2)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td>
                      <td align="char" rowspan="1" colspan="1">20 (67%)</td>
                      <td align="char" rowspan="1" colspan="1">10 (33%)</td>
                      <td align="char" rowspan="1" colspan="1">17(65%)</td>
                      <td align="char" rowspan="1" colspan="1">9 (35%)</td>
                      <td align="char" rowspan="1" colspan="1">10 (59%)</td>
                      <td align="char" rowspan="1" colspan="1">7 (41%)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Minority, <italic toggle="yes">n</italic> (%)</td>
                      <td align="char" rowspan="1" colspan="1">18 (58%)</td>
                      <td align="char" rowspan="1" colspan="1">13 (42%)</td>
                      <td align="char" rowspan="1" colspan="1">16 (53%)</td>
                      <td align="char" rowspan="1" colspan="1">14 (47%)</td>
                      <td align="char" rowspan="1" colspan="1">17 (59%)</td>
                      <td align="char" rowspan="1" colspan="1">12 (41%)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Duration of hypertension, years</td>
                      <td align="char" rowspan="1" colspan="1">23.2 (12.5)</td>
                      <td align="char" rowspan="1" colspan="1">25.5 (12.2)</td>
                      <td align="char" rowspan="1" colspan="1">20.3 (12.0)</td>
                      <td align="char" rowspan="1" colspan="1">18.1 (8.1)</td>
                      <td align="char" rowspan="1" colspan="1">22.9 (13.4)</td>
                      <td align="char" rowspan="1" colspan="1">25.7 (10.6)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <bold>Clinical characteristics</bold>
                      </td>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Clinic systolic blood pressure, mmHg</td>
                      <td align="char" rowspan="1" colspan="1">136.6 (9.7)</td>
                      <td align="char" rowspan="1" colspan="1">138.7 (10.8)</td>
                      <td align="char" rowspan="1" colspan="1">141.1 (11.2)</td>
                      <td align="char" rowspan="1" colspan="1">139.2 (8.5)</td>
                      <td align="char" rowspan="1" colspan="1">138.8 (10.3)</td>
                      <td align="char" rowspan="1" colspan="1">143.9 (10.1)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Clinic diastolic blood pressure, mmHg</td>
                      <td align="char" rowspan="1" colspan="1">77.6 (10.2)</td>
                      <td align="char" rowspan="1" colspan="1">81.0 (10.0)</td>
                      <td align="char" rowspan="1" colspan="1">79.2 (9.2)</td>
                      <td align="char" rowspan="1" colspan="1">78.4 (8.5)</td>
                      <td align="char" rowspan="1" colspan="1">80.1 (8.2)</td>
                      <td align="char" rowspan="1" colspan="1">80.9 (6.7)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Body mass index, kg/m2<xref rid="jch14591-tbl1-note-0001" ref-type="table-fn">**</xref>
</td>
                      <td align="char" rowspan="1" colspan="1">32.4 (5.0)</td>
                      <td align="char" rowspan="1" colspan="1">35.7 (5.3)</td>
                      <td align="char" rowspan="1" colspan="1">36.8 (5.1)</td>
                      <td align="char" rowspan="1" colspan="1">35.1 (5.0)</td>
                      <td align="char" rowspan="1" colspan="1">39.5 (5.8)</td>
                      <td align="char" rowspan="1" colspan="1">38.1 (5.2)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Waist to hip ratio, %</td>
                      <td align="char" rowspan="1" colspan="1">98.7 (6.0)</td>
                      <td align="char" rowspan="1" colspan="1">98.9 (8.4)</td>
                      <td align="char" rowspan="1" colspan="1">98.2 (6.3)</td>
                      <td align="char" rowspan="1" colspan="1">96.9 (6.1)</td>
                      <td align="char" rowspan="1" colspan="1">97.1 (6.8)</td>
                      <td align="char" rowspan="1" colspan="1">99.6 (5.6)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Homeostatic model of insulin resistance, U<xref rid="jch14591-tbl1-note-0001" ref-type="table-fn">**</xref>
</td>
                      <td align="char" rowspan="1" colspan="1">3.6 (1.9)</td>
                      <td align="char" rowspan="1" colspan="1">3.8 (2.2)</td>
                      <td align="char" rowspan="1" colspan="1">5.2 (2.8)</td>
                      <td align="char" rowspan="1" colspan="1">5.2 (3.9)</td>
                      <td align="char" rowspan="1" colspan="1">5.8 (2.7)</td>
                      <td align="char" rowspan="1" colspan="1">5.1 (4.0)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Framingham stroke risk profile score</td>
                      <td align="char" rowspan="1" colspan="1">10.4 (3.4)</td>
                      <td align="char" rowspan="1" colspan="1">9.6 (3.2)</td>
                      <td align="char" rowspan="1" colspan="1">9.9 (3.7)</td>
                      <td align="char" rowspan="1" colspan="1">11.3 (3.6)</td>
                      <td align="char" rowspan="1" colspan="1">9.5 (3.2)</td>
                      <td align="char" rowspan="1" colspan="1">10.6 (2.5)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Atherosclerotic risk profile score</td>
                      <td align="char" rowspan="1" colspan="1">13.5 (9.0)</td>
                      <td align="char" rowspan="1" colspan="1">10.6 (7.6)</td>
                      <td align="char" rowspan="1" colspan="1">14.9 (8.3)</td>
                      <td align="char" rowspan="1" colspan="1">14.1 (8.2)</td>
                      <td align="char" rowspan="1" colspan="1">11.8 (6.4)</td>
                      <td align="char" rowspan="1" colspan="1">14.4 (9.7)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Creatinine, mg/dl</td>
                      <td align="char" rowspan="1" colspan="1">84.7 (31.7)</td>
                      <td align="char" rowspan="1" colspan="1">99.5 (48.7)</td>
                      <td align="char" rowspan="1" colspan="1">77.5 (30.8)</td>
                      <td align="char" rowspan="1" colspan="1">86.7 (50.0)</td>
                      <td align="char" rowspan="1" colspan="1">79.0 (38.1)</td>
                      <td align="char" rowspan="1" colspan="1">85.1 (32.3)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <bold>Cognitive characteristics</bold>
                      </td>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                      <td align="char" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Montreal cognitive assessment score</td>
                      <td align="char" rowspan="1" colspan="1">25.5 (2.5)</td>
                      <td align="char" rowspan="1" colspan="1">25.5 (2.0)</td>
                      <td align="char" rowspan="1" colspan="1">25.9 (2.2)</td>
                      <td align="char" rowspan="1" colspan="1">25.5 (2.6)</td>
                      <td align="char" rowspan="1" colspan="1">25.5 (2.6)</td>
                      <td align="char" rowspan="1" colspan="1">23.5 (4.0)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Executive function/learning score, mean rank</td>
                      <td align="char" rowspan="1" colspan="1">68.9 (20.8)</td>
                      <td align="char" rowspan="1" colspan="1">68.3 (26.4)</td>
                      <td align="char" rowspan="1" colspan="1">69.7 (22.7)</td>
                      <td align="char" rowspan="1" colspan="1">65.5 (21.6)</td>
                      <td align="char" rowspan="1" colspan="1">74.7 (15.3)</td>
                      <td align="char" rowspan="1" colspan="1">67.9 (21.6)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Processing speed score, mean rank</td>
                      <td align="char" rowspan="1" colspan="1">74.7 (31.5)</td>
                      <td align="char" rowspan="1" colspan="1">63.1 (33.7)</td>
                      <td align="char" rowspan="1" colspan="1">74.3 (27.1)</td>
                      <td align="char" rowspan="1" colspan="1">68.9 (29.7)</td>
                      <td align="char" rowspan="1" colspan="1">69.4 (23.2)</td>
                      <td align="char" rowspan="1" colspan="1">60.2 (35.1)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Memory score, mean rank</td>
                      <td align="char" rowspan="1" colspan="1">66.8 (29.2)</td>
                      <td align="char" rowspan="1" colspan="1">61.6 (35.0)</td>
                      <td align="char" rowspan="1" colspan="1">70.3 (27.6)</td>
                      <td align="char" rowspan="1" colspan="1">70.8 (30.8)</td>
                      <td align="char" rowspan="1" colspan="1">77.4 (26.1)</td>
                      <td align="char" rowspan="1" colspan="1">67.2 (32.8)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="jch14591-tbl1-note-0001">
                    <p>Omnibus test for differences between CRP groups: **<italic toggle="yes">P</italic> &lt; .01; *<italic toggle="yes">P</italic> &lt; .05.</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
                </permissions>
              </table-wrap>
              <sec id="jch14591-sec-0050">
                <label>3.1</label>
                <title>Baseline inflammation and treatment‐related cognitive changes</title>
                <p>Examination of treatment‐related changes in cognitive function revealed that the effects of treatment on Executive Function and Learning were moderated by baseline hsCRP levels (<italic toggle="yes">P</italic> = .049); there was no evidence of moderation for Processing Speed (<italic toggle="yes">P</italic> = .897) or Memory (<italic toggle="yes">P</italic> = .936). Explanatory analyses revealed that treatment group differences were minimal among those with low baseline CRP levels and that treatment group differences were greater among those participants with higher baseline CRP levels. Specifically, comparison of post‐treatment performance between those in C‐LIFE vs. SEPA were smallest for low hsCRP (<italic toggle="yes">d</italic> = 0.12; 67.5 [63.5, 71.5] vs. 69.1 [61.7, 76.4]), intermediate for mildly elevated hsCRP (<italic toggle="yes">d</italic> = 0.43; 67.9 [63.4, 72.3] vs. 62.3 [56.6, 67.9]), and greatest for moderately elevated hsCRP (<italic toggle="yes">d</italic> = 0.81; 64.2 [59.5, 68.9] vs. 53.6 [46.4, 60.9]). Using demographically‐corrected normative data, among individuals in the higher hsCRP group, these differences corresponded to improvements of 1.5 (−0.2, 3.1) and 0.2 (−2.4, 2.8) in the C‐LIFE and SEPA groups, respectively. In addition, we observed a non‐linear association between hsCRP and changes in Executive Function and Learning across groups (<italic toggle="yes">P</italic> = .019 for restrictive cubic spline test), such that group effects diverged at approximate hsCRP levels of 3.0 and 7.0 mg/L, respectively (Figure <xref rid="jch14591-fig-0001" ref-type="fig">1</xref>). Examination of follow‐up neurocognitive outcomes collected at one‐year following randomization were also examined. We found that hsCRP continued to moderate the effects of treatment when one‐year follow‐up data were incorporated as an additional repeated measures outcome (P = .030). Results for individuals with low, mild, and moderate hsCRP levels demonstrated better performance in C‐LIFE vs. SEPA at both T2 (C‐LIFE: 73.3 [69.1, 77.5], 73.4 [68.8, 78.1], and 69.8 [64.8, 74.7] vs. SEPA: 74.8 [67.1, 82.4], 67.8 [61.8, 73.7], and 58.2 [50.6, 65.9]) and T3 (C‐LIFE: 73.1 [68.1, 78.1], 68.5 [62.9, 74.1], and 68.8 [62.5, 75.1], vs. SEPA: 75.4 [65.8, 85.0], 69.6 [62.6, 76.6], and 58.2 [50.2, 66.2]).</p>
                <fig position="float" fig-type="FIGURE" id="jch14591-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Treatment group differences across levels of baseline inflammation from adjusted regression models (C‐LIFE = blue; SEPA = red). As shown, post‐treatment Executive Function performance (A) and changes in Executive Function (B) worsened in the SEPA group at higher levels of baseline CRP. In contrast, changes were relatively consistent in C‐LIFE across baseline CRP levels</p>
                  </caption>
                  <graphic xlink:href="JCH-25-106-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>Exploratory analyses of putative treatment changes revealed that the moderating effects of treatment were paralleled by moderating effects of aerobic fitness improvements (<italic toggle="yes">P</italic> = .045), such that the effects of improved peak oxygen consumption on Executive Function and Learning were observed among individuals with moderately elevated baseline hsCRP (<italic toggle="yes">r</italic> = 0.29, <italic toggle="yes">P</italic> = .038), but not among those with mild (<italic toggle="yes">r</italic> = 0.04, <italic toggle="yes">P</italic> = .619), or low levels (<italic toggle="yes">r</italic> = 0.03, <italic toggle="yes">P</italic> = .775). No moderating effects were observed for weight loss, dietary changes, or BP reductions. We also found no evidence that treatment differentially improved hsCRP levels, or that reductions in hsCRP from pre‐to‐post treatment associated with improvements in Executive Function and Learning (<italic toggle="yes">B</italic> = −0.10, <italic toggle="yes">P</italic> = .192).</p>
              </sec>
            </sec>
            <sec id="jch14591-sec-0060">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>The present findings extend prior work demonstrating that basal levels of elevated peripheral inflammation may represent an intermediate phenotype of risk for cognitive decline.<xref rid="jch14591-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jch14591-bib-0010" ref-type="bibr"><sup>10</sup></xref> We found that individuals with higher levels of hsCRP at baseline demonstrated greater improvements in Executive Function/Learning following participation in an intensive lifestyle intervention. These findings may suggest that inflammatory profiles may help identify individuals more likely to benefit cognitively from lifestyle modification using exercise and dietary modification.</p>
              <p>Prior epidemiological studies have suggested that elevated inflammatory profiles may interact with comorbid cardiometabolic risk factors to adversely affect cognitive functioning,<xref rid="jch14591-bib-0011" ref-type="bibr"><sup>11</sup></xref> although no prior randomized trials have examined such individual differences. CVD risk factors, including hypertension and obesity, have consistently been linked to cognitive decline through an array of interrelated mechanisms including impaired insulin sensitivity and elevated inflammation.<xref rid="jch14591-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jch14591-bib-0013" ref-type="bibr"><sup>13</sup></xref> Because of the overlapping influences of CVD risk, obesity, and metabolic dysfunction on inflammation, emerging data have suggested that elevated inflammatory markers among individuals with CVD risk factors may represent a viable intermediate phenotype of ADRD risk, identifying adults with a higher likelihood of ADRD through the convergent influence of multiple risk pathways.<xref rid="jch14591-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jch14591-bib-0010" ref-type="bibr"><sup>10</sup></xref> Among individuals with type‐2 diabetes, for example, greater plasma hsCRP concentrations continue to predictive of subsequent cognitive decline,<xref rid="jch14591-bib-0014" ref-type="bibr"><sup>14</sup></xref> suggesting that a pro‐inflammatory state confers ADRD risk beyond the influence of metabolic dysfunction. Similarly, prior systematic reviews have suggested that the linkages between obesity and impaired executive function are likely indirect or amplified by comorbid systemic risk factors, suggesting elevated inflammation may represent a downstream, convergent pathway of risk driven by an array of CVD risk markers.<xref rid="jch14591-bib-0015" ref-type="bibr"><sup>15</sup></xref> This is consistent with findings in the present study among sedentary adults with RH, as neither baseline obesity (<italic toggle="yes">P</italic> = .656) nor insulin sensitivity (<italic toggle="yes">P</italic> = .444) moderated treatment changes on Executive Function, despite both associating with baseline hsCRP concentrations. Our findings therefore extend prior research by demonstrating that elevated inflammation in the presence of CVD risk factors may impact cognitive changes following lifestyle modification, providing initial evidence to refine targeted treatment approaches.</p>
              <sec id="jch14591-sec-0070">
                <label>4.1</label>
                <title>Limitations</title>
                <p>First, the intervention was relatively brief and future studies will need to examine whether individual treatment differences based on inflammatory profiles persisted over follow‐up. Second, our assessment of inflammation was limited to hsCRP, whereas future studies should collect a richer array of inflammatory markers. However, we note that when inflammatory data from a subset of participants who also had tumor necrosis factor‐alpha levels collected were integrated with hsCRP, our observation that baseline inflammation moderated the effects of treatment persisted (<italic toggle="yes">P</italic> = .039). Third, our assessment of inflammatory markers was limited to peripheral serum markers and may therefore not reflect inflammation within the central nervous system. Finally, our 2:1 randomization resulted in a 1.8:1 ratio of C‐LIFE to SEPA participants, despite demonstrating very few baseline group differences.<xref rid="jch14591-bib-0006" ref-type="bibr"><sup>6</sup></xref>
</p>
              </sec>
            </sec>
            <sec id="jch14591-sec-0080">
              <label>5</label>
              <title>CONCLUSION</title>
              <p>The findings in this report extend to previous studies on the role of inflammation in cognitive dysfunction by demonstrating that the beneficial effects of lifestyle modification may be greater among individuals with greater levels of inflammation. These findings, if replicated, may help inform targeted treatments to reduce ADRD among middle‐aged and older adults with CVD risk factors.</p>
            </sec>
            <sec sec-type="COI-statement" id="jch14591-sec-0100">
              <title>CONFLICT OF INTEREST</title>
              <p>None.</p>
            </sec>
          </body>
          <back>
            <ack id="jch14591-sec-0090">
              <title>ACKNOWLEDGMENT</title>
              <p>Supported by Grants HL122836 and HL130237 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda.</p>
            </ack>
            <ref-list id="jch14591-bibl-0001">
              <title>REFERENCES</title>
              <ref id="jch14591-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0001"><collab collab-type="authors">Collaborators GRF</collab>
. <article-title>Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015</article-title>. <source>Lancet (London)</source>. <year>2016</year>;<volume>388</volume>:<fpage>1659</fpage>.</mixed-citation>
              </ref>
              <ref id="jch14591-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0002"><string-name><surname>Pathan</surname><given-names>MK</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DL</given-names></string-name>. <article-title>Resistant hypertension: where are we now and where do we go from here?</article-title><source>Integr Blood Press Control</source>. <year>2020</year>; <volume>13</volume>: <fpage>83</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">32801854</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0003"><string-name><surname>Alfaddagh</surname><given-names>A</given-names></string-name>, <string-name><surname>Martin</surname><given-names>SS</given-names></string-name>, <string-name><surname>Leucker</surname><given-names>TM</given-names></string-name>, et al. <article-title>Inflammation and cardiovascular disease: from mechanisms to therapeutics</article-title>. <source>Am J Prev Cardiol</source>. <year>2020</year>;<volume>4</volume>:<elocation-id>100130</elocation-id>.<pub-id pub-id-type="pmid">34327481</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0004">Tangestani Fard M, <string-name><surname>Stough</surname><given-names>C</given-names></string-name>. <article-title>A review and hypothesized model of the mechanisms that underpin the relationship between inflammation and cognition in the elderly</article-title>. <source>Front Aging Neuro</source>. <year>2019</year>;<volume>11</volume>:<fpage>56</fpage>.</mixed-citation>
              </ref>
              <ref id="jch14591-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0005"><string-name><surname>Hay</surname><given-names>M</given-names></string-name>, <string-name><surname>Barnes</surname><given-names>C</given-names></string-name>, <string-name><surname>Huentelman</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>R</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>L</given-names></string-name>. <article-title>Hypertension and age‐related cognitive impairment: common risk factors and a role for precision aging</article-title>. <source>Curr Hyperten Rep</source>. <year>2020</year>;<volume>22</volume>:<fpage>1</fpage>‐<lpage>14</lpage>.</mixed-citation>
              </ref>
              <ref id="jch14591-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0006"><string-name><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hinderliter</surname><given-names>AL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>PJ</given-names></string-name>, et al. <article-title>Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial</article-title>. <source>Circulation</source>. <year>2021</year>;<volume>144</volume>:<fpage>1212</fpage>‐<lpage>1226</lpage>.<pub-id pub-id-type="pmid">34565172</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0007"><string-name><surname>Smith</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Sherwood</surname><given-names>A</given-names></string-name>, <string-name><surname>Hinderliter</surname><given-names>AL</given-names></string-name>, et al. <article-title>Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial</article-title>. <source>J Hypertens</source>. <year>2022</year>;<volume>40</volume>:<fpage>1359</fpage>‐<lpage>1368</lpage>.<pub-id pub-id-type="pmid">35703293</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0008"><string-name><surname>Smith</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Blumenthal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Babyak</surname><given-names>MA</given-names></string-name>, et al. <article-title>Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure</article-title>. <source>Hypertension</source>. <year>2010</year>;<volume>55</volume>:<fpage>1331</fpage>‐<lpage>1338</lpage>.<pub-id pub-id-type="pmid">20305128</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0009"><string-name><surname>Nordengen</surname><given-names>K</given-names></string-name>, <string-name><surname>Palhaugen</surname><given-names>L</given-names></string-name>, <string-name><surname>Bettella</surname><given-names>F</given-names></string-name>, et al. <article-title>Phenotype‐informed polygenic risk scores are associated with worse outcome in individuals at risk of Alzheimer's disease</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2022</year>;<volume>14</volume>:<elocation-id>e12350</elocation-id>.<pub-id pub-id-type="pmid">35991219</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0010"><string-name><surname>Desikan</surname><given-names>RS</given-names></string-name>, <string-name><surname>Schork</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Polygenic overlap between C‐reactive protein, plasma lipids, and Alzheimer disease</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>131</volume>:<fpage>2061</fpage>‐<lpage>2069</lpage>.<pub-id pub-id-type="pmid">25862742</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0011"><string-name><surname>Yaffe</surname><given-names>K</given-names></string-name>, <string-name><surname>Kanaya</surname><given-names>A</given-names></string-name>, <string-name><surname>Lindquist</surname><given-names>K</given-names></string-name>, et al. <article-title>The metabolic syndrome, inflammation, and risk of cognitive decline</article-title>. <source>Jama</source>. <year>2004</year>;<volume>292</volume>:<fpage>2237</fpage>‐<lpage>2242</lpage>.<pub-id pub-id-type="pmid">15536110</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0012"><string-name><surname>Cholerton</surname><given-names>B</given-names></string-name>, <string-name><surname>Baker</surname><given-names>LD</given-names></string-name>, <string-name><surname>Craft</surname><given-names>S</given-names></string-name>. <article-title>Insulin, cognition, and dementia</article-title>. <source>Euro J Pharm</source>. <year>2013</year>;<volume>719</volume>:<fpage>170</fpage>‐<lpage>179</lpage>.</mixed-citation>
              </ref>
              <ref id="jch14591-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0013"><string-name><surname>Chen</surname><given-names>ST</given-names></string-name>, <string-name><surname>Siddarth</surname><given-names>P</given-names></string-name>, <string-name><surname>Ercoli</surname><given-names>LM</given-names></string-name>, et al. <article-title>Modifiable risk factors for Alzheimer disease and subjective memory impairment across age groups</article-title>. <source>PloS One</source>. <year>2014</year>;<volume>9</volume>:<elocation-id>e98630</elocation-id>.<pub-id pub-id-type="pmid">24896243</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0014"><string-name><surname>Sluiman</surname><given-names>AJ</given-names></string-name>, <string-name><surname>McLachlan</surname><given-names>S</given-names></string-name>, <string-name><surname>Forster</surname><given-names>RB</given-names></string-name>, et al. <article-title>Higher baseline inflammatory marker levels predict greater cognitive decline in older people with type 2 diabetes: year 10 follow‐up of the Edinburgh Type 2 Diabetes Study</article-title>. <source>Diabetologia</source>. <year>2022</year>;<volume>65</volume>:<fpage>467</fpage>‐<lpage>476</lpage>.<pub-id pub-id-type="pmid">34932135</pub-id></mixed-citation>
              </ref>
              <ref id="jch14591-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jch14591-cit-0015"><string-name><surname>Fitzpatrick</surname><given-names>S</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>S</given-names></string-name>, <string-name><surname>Serpell</surname><given-names>L</given-names></string-name>. <article-title>Systematic review: are overweight and obese individuals impaired on behavioural tasks of executive functioning?</article-title><source>Neuropsych Rev</source>. <year>2013</year>;<volume>23</volume>:<fpage>138</fpage>‐<lpage>156</lpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
